Bousiges Olivier, Blanc Frédéric
Hôpitaux Universitaires de Strasbourg, Laboratoire de biochimie et biologie moléculaire ; CNRS, Laboratoire de neurosciences cognitives et adaptatives (LNCA), UMR7364, Strasbourg, France.
Hôpitaux Universitaires de Strasbourg, Centre mémoire de ressource et de recherche (CMRR), Hôpital de jour, Pôle de gériatrie ; CNRS, Laboratoire ICube UMR 7357 ; Fédération de médecine translationnelle de Strasbourg (FMTS), Équipe IMIS/Neurocrypto, Strasbourg, France.
Geriatr Psychol Neuropsychiatr Vieil. 2018 Sep 1;16(3):305-310. doi: 10.1684/pnv.2018.0750.
Dementia with Lewy body (DLB) is the second most common form of dementia after Alzheimer's disease (AD), accounting for 15% to 20% of neuropathologically defined cases. Two-thirds of the patients affected are not or misdiagnosed. In this review, we evaluate the discriminatory power of cerebrospinal fluid (CSF) alpha-synuclein by focusing more specifically on differential diagnosis between DLB and AD. Alpha-synuclein assay in the CSF has an interest in the discrimination between DLB and AD but not in segregation between DLB and healthy elderly subjects. The development of biomarkers such as phospho-alpha-synuclein and oligomeric alpha-synuclein should help to reinforce this discrimination power.
路易体痴呆（DLB）是仅次于阿尔茨海默病（AD）的第二常见痴呆形式，在神经病理学确诊的病例中占15%至20%。三分之二的患者未被诊断或被误诊。在本综述中，我们更具体地通过关注DLB与AD之间的鉴别诊断来评估脑脊液（CSF）α-突触核蛋白的鉴别能力。CSF中的α-突触核蛋白检测对DLB与AD的鉴别有意义，但对DLB与健康老年受试者的区分无意义。磷酸化α-突触核蛋白和寡聚体α-突触核蛋白等生物标志物的开发应有助于增强这种鉴别能力。
